Explore Treatment Approaches for Triple Negative Breast Cancer

Triple negative breast cancer, often called TNBC, is identified by the absence of three common biological markers used in breast cancer treatment. Since the cancer cells do not respond to hormone therapy or HER2 targeted medicines in the same way as other breast cancer types, treatment strategies may differ. The treatment approach depends on factors such as the cancer stage, tumor size, whether cancer has spread, genetic characteristics, previous treatments, and the person's general health.

Surgery and Chemotherapy Approaches

Surgery and chemotherapy are commonly considered in the treatment of triple negative breast cancer. For early stage disease, treatment may involve removing the tumor through breast conserving surgery or removing the breast through mastectomy. Lymph nodes may also be evaluated to determine whether cancer cells have spread beyond the original tumor.

Chemotherapy may be given before surgery, known as neoadjuvant chemotherapy, or after surgery, known as adjuvant chemotherapy. Giving chemotherapy before surgery can help reduce the size of some tumors and may provide information about how the cancer responds to treatment. The treatment plan is based on individual clinical findings and medical guidance.

• Breast conserving surgery may remove the tumor while preserving as much healthy breast tissue as possible.
• Mastectomy involves surgical removal of breast tissue and may be recommended in certain situations.
• Neoadjuvant chemotherapy may be used before surgery to treat the tumor and potentially reduce its size.
• Adjuvant chemotherapy may be recommended after surgery to address cancer cells that may remain in the body.
• Radiation therapy may be considered after surgery depending on the tumor, lymph node involvement, and other clinical factors.

Immunotherapy and Targeted Treatment Options

Advances in cancer research have expanded the range of treatments that may be considered for some people with triple negative breast cancer. Immunotherapy works by helping the immune system recognize or respond to cancer cells and may be used for certain eligible patients. Its use can depend on the stage of cancer and specific characteristics of the tumor.

Targeted treatments may also be considered when genetic or molecular testing identifies characteristics that can influence treatment selection. For example, some patients with inherited BRCA gene changes may be eligible for particular targeted medicines. In advanced or metastatic TNBC, treatment planning may also involve additional systemic therapies based on previous treatment history and tumor testing.

• Immunotherapy may be combined with chemotherapy for certain eligible patients.
• Genetic testing can help identify inherited changes that may influence treatment discussions.
• Targeted medicines may be considered when specific genetic or molecular features are present.
• Antibody drug conjugates may be treatment options in certain advanced disease settings.
• Clinical trials may provide access to research studies evaluating new treatment approaches.

Triple negative breast cancer treatment continues to evolve as researchers learn more about tumor biology and develop new therapeutic approaches. Regular communication with an oncology team can help patients understand the purpose, possible benefits, and potential side effects of each treatment option. Individual treatment decisions should be based on professional medical evaluation, current clinical guidelines, and the specific characteristics of the cancer. This article is provided for informational purposes only and does not offer medical, sales, or treatment services.